anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Parkinson's disease is a common neurodegenerative disease and movement disorder. Due to the degeneration of basal ganglia, patients with Parkinson's disease also demonstrate internal rhythm dysfunction, thus will lead to difficulty in rhythmic movements such as ambulation. For improving the rhythmic movement problem, auditory cues are often used in clinical setting and shows benefits in ambulation and freezing problems. Previous studies often use finger tapping test and ambulation to assess the rhythmic movement problem. No study uses stepping in place movements as a test to examine rhythmic problem. Little study investigates the effects of auditory cues on brain cortical excitability. In this cross-over study, participants will receive 2 times of training include stepping-in-place exercise with and without auditory cues in random orders. Auditory cues are given via the metronome. There is one-week wash-out period between two trainings. Movement tests such as walking and stepping-in-place and transcranial magnetic stimulation (TMS) are carried out before and after each training.

The investigators hypothesize the variation of rhythmic movements such as walking and stepping-in-place will be reduced more, and the cortical excitability would be modulated after the training with auditory cues, comparing with the other training without auditory cues.
OBJECTIVES: The aim of this research was to find the acupoint combinations of manual and electro-acupuncture to treat chemotherapy-induced nausea and vomiting via the complex networks analysis.
METHODS: We conducted searches using PubMed, ScienceDirect, MEDLINE, Ovid, spring, Wiley, EMBASE, the Chinese biomedicine database, VIP information network, and China National Knowledge Infrastructure from the establishment of the databases to the August, 2023. Information about titles, journals, interventions, and main acupoints was extracted using the self-established "acupoint for prevention CINV data base" powered by EpiData. According to the level of literature evidence and sample size, the clinical trials and weights of the outcome indicators including nausea/vomiting efficiency were combined. After identifying articles, literature processing and complex network analysis were conducted. The degree distribution of each node, the probability distribution of node degree, the node clustering coefficient, and the distance matrix are calculated by software.
RESULTS: Of the 4001 screened publications, 489 were eligible after careful selection. Our result showed the acupoints ST36 and PC6 were the most common combination acupoints in both electro and manual acupuncture. In terms of efficiency, ST36, PC6, and CV12 are significantly effective acupoints for manual acupuncture, and the PC6 and ST36 are effective acupoint for electro-acupuncture.
CONCLUSIONS: We found that the near-far collocation method has been commonly used for different types of acupuncture treatment in CINV. Zhongwan, Shangwan, and Liangmen have been mainly used as local acupoints, while Neiguan, Hegu, Quchi, Zusanli, Gongsun, TaiChong, and Neiguan have been mainly used as distal acupoints. From the effect analysis, acupuncture treatment of nausea manual acupuncture effect is better; acupuncture treatment of vomiting or electro-acupuncture effect is better.
PURPOSE: This study aimed to determine the presence of peripheral spondyloarthritis and investigate the clinical characteristics of patients with concurrent peripheral spondyloarthritis in those presenting with refractory plantar fasciitis and Achilles tendinopathy by conducting human leukocyte antigen B-27 (HLA-B27) testing.
METHODS: This retrospective study aimed to investigate patients who complained of persistent pain and significant limitations in daily activities due to their respective foot pain, despite receiving conservative treatment for over one year under the diagnosis of plantar fasciitis or insertional Achilles tendinopathy. The study included 63 patients who underwent HLA-B27 testing. The patients were classified into two groups based on the presence or absence of HLA-B27 positivity. The Mann-Whitney U test assessed significant relationships between continuous variables, and the chi-square test was used to compare categorical variables.
RESULTS: Among the 63 included patients, HLA-B27 positivity was confirmed in 11 patients (17.5%), which was significantly associated with a lower average age (22.8 years versus 31.7 years, P = 0.01) and a substantially lower proportion of females compared to HLA-B27-negative patients (9.1% vs. 25.0%, P = 0.001). Ten of the 11 patients initiated treatment with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) combined with oral steroids as the first-line medication after being diagnosed as HLA-B27 positive. Six patients experienced pain relief with the first-line medication (60%). Four patients who did not achieve pain control with the first-line medication received tumour necrosis factor-alpha inhibitors as the second-line medication. Two patients experienced pain relief, while two experienced reduced but persistent pain.
CONCLUSIONS: Among the patients with "refractory" plantar fasciitis and insertional Achilles tendinopathy, 17.5% were diagnosed with peripheral spondyloarthritis. Patients diagnosed with peripheral spondyloarthritis had a higher proportion of men and relatively younger mean age compared to those without the diagnosis. Approximately 70% of these patients achieved symptom improvement in foot and ankle joints by taking conventional synthetic DMARDs, TNF-α inhibitors, or both appropriate for spondyloarthritis.
<P>PROBLEM TO BE SOLVED: To obtain an endoplasmic reticulum protein having a disulfide bond reduction activity and to provide a method for decomposing and/or removing a misfolded protein in cells by the protein.  <P>SOLUTION: Protein ERdj5 having disulfide activity is purified. The endoplasmic reticulum protein exhibits reduction activity. The gene is directly expressed in cells to directly exhibit the decomposition promotion activity of the misfolded protein. Namely, a known endoplasmic reticulum protein ERdj5 has reduction power differently from the conventionally reported result and is elucidated to promote the decomposition of protein misfolded in the cells.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Diclofenac potassium for oral solution is a nonsteroidal anti-inflammatory drug, available as a buffered soluble powder, designed to be mixed with water prior to oral administration. Diclofenac potassium for oral solution is a white to off-white, buffered, flavored powder for oral solution packaged in individual unit dose packets.   
The chemical name is potassium [o-(2,6-dichloroanilino) phenyl] acetate. The molecular mass is 334.24 g/mole. Its molecular formula is C 14H 10Cl 2NKO 2, and it has the following structure. 

  
The inactive ingredients in diclofenac potassium for oral solution include: flavoring agent (peppermint), glyceryl behenate, mannitol, sucralose and tribasic sodium phosphate anhydrous.
<P>PROBLEM TO BE SOLVED: To obtain a suspended agrochemical liquid composition which contains a mixture of sulfur with pyrethrin and/or pyrethroid and is safe for the environment.  <P>SOLUTION: This agrochemical composition is effective in controlling blights of plants and harmful organisms such as bugs and ticks. The composition can be prepared as a concentrated compounds or a compound for immediate use. The compounds are supplied to each plant in both indoor and outdoor to control blights of plants and harmful organisms such as bugs and ticks, reducing damage to plants due to the harmful organisms. The compounds can be supplied to each plant with minimum toxicity to plants (damage to plants) and do not leave an intolerable and visible sulfur residue.  <P>COPYRIGHT: (C)2003,JPO
The Roux-en-Y gastric bypass (RNYGB) is the most commonly performed bariatric procedure to treat morbid obesity 1. Numerous studies have documented the effectiveness of RNYGB in promoting excess weight loss (EWL) typically in the 65-80% range after 1.5 to 2 years 1. Despite the favorable short-term outcomes of this bariatric surgical procedure, approximately 10-40% of patients do not achieve successful long-term weight loss 2. The weight regain occurs typically within 2 to 7 years after RNYGB surgery and is associated primarily with dilation of the gastric pouch or stoma 3, 4. Several open and laparoscopic bariatric revision procedures have been used in an attempt to correct these dilations, but they all have been associated with serious complications such as perforations, obstruction, staple line disruption, blind loop syndrome, stoma ulcer, and incisional hernias 2, 5, 6. Because of this high rate of morbidity associated with revisional gastric bypass surgery, less invasive endoscopic procedures may become a preferred approach for weight regain after RNYGB 7, 8.

The StomaphyX delivery system with SerosaFuse fasteners consist of an ergonomic, flexible fastener delivery device and sterile polypropylene fastener implants. The unit is provided sterile and is a single use device. The polypropylene fasteners are proprietary and function only with the StomaphyX device. The device uses vacuum to invaginate tissue through a port into a chamber and fasten it using the H shaped polypropylene fasteners. The fastener delivery subsystem is comprised of 3 elements: stylet, pusher, and internal lumens. They run the length of the device, the pusher being a hollow tube that rides over the length of the stylet, both riding in the lumen. The stylet is sharp at the distal tip to pierce tissue. The fastener is loaded by snapping it onto the stylet in the loading port of the handle. When pushed by the operator, the stylet carries the fastener down the lumen which runs from the proximal handle assembly to the distal tissue port where it will eventually be deployed into the tissue. Durability of the SerosaFuse fasteners has been demonstrated during several clinical studies utilizing the EsophyX device 9-12.

Reason for Conducting the Present Study: The goal of this study was to investigate the safety and effectiveness of the StomaphyX device for revisional natural orifice surgery of the gastric pouch and gastrojejunostomy anastomosis (stoma) in RNYGB patients to reduce regained weight.
Single embryo transfer and freezing of surplus embryos has lowered twin birth rates after in vitro fertilization (IVF) to a level of less than 5% in Denmark. However, several treatments with repeated frozen embryo transfers (FET) before a viable pregnancy is confirmed are burdensome to the patients. New freezing techniques has optimized the quality of the embryo transferred in FET cycles, but optimization of the endometrium in the luteal phase is still lacking behind. In a mNC-FET, which is the routine in many clinics, ovulation is induced with an hCG injection when the leading follicle is ≥17 mm. The hCG trigger is important for controlling the time of ovulation, but triggering an unhealthy follicle at an inappropriate time may cause luteal phase insufficiency and thus suboptimal function of the endometrium. Danish public fertility clinics are not routinely using progesterone supplementation in mNC-FET, but there may be a rationale to do so, and some implantations may be rescued. In this study we will compare live birth rates in mNC-FET with and without progesterone supplementation in the luteal phase, and further we will explore the optimal timing of blastocyst warming and transfer by comparing embryo transfer at hCG trigger +6 days versus +7 days. This is a superiority study with the aim to detect an increase in live birth rates of 10%. Hence, this adequately powered RCT may make a major contribution to knowledge on mNC-FET to the benefits of patients. We will include 604 patients divided 1:1 (302:302) in each arm +/- progesterone and these will further be divided 1:1 in blastocyst warming and transfer +6 and +7 days after hCG injection. The primary endpoint is live birth rate per transfer.
The process of recovering from critical illness is complex. The physical and psychological consequences of surviving critical illness can extend past the intensive unit care stay and after hospital discharge. For a critically ill patient, their first transition is being discharged from intensive care to a general ward and is one of the most stressful transitions they experience. They are required to adjust both physically and psychologically as they begin an uncertain journey to recovery. Research on the patient experience has identified vulnerability, hopelessness, fear of the unknown and anxiety as key features of this transition. A need for information and empowerment in the recovery process are highlighted for developing treatment strategies. It is suggested that there is a relationship between physical problems and psychological symptoms but this has not been researched. There is also limited evidence to guide clinicians in treatment strategy choice for these patients. This pilot study aims to test the effectiveness of a physiotherapy directed Rehabilitation after Critical illness Assisted discharge Pack (RECAP) on the physical and psychological function of patients recovering from critical illness in the first three weeks post discharge from the ICU to the general ward area. The study will rely on a randomized controlled clinical trial design, with patients assigned to either a "usual care" control group vs. the treatment group. Individuals in the treatment group will receive "usual care" plus a RECAP pack at ICU discharge with once weekly follow up with an ICU physiotherapist. The intervention group will receive the RECAP plus standard physiotherapy for the first three weeks after intensive care stay and the control group will receive standard physiotherapy alone. Outcome measures used will be the Functional Independence Measure (FIM) and State Anxiety Inventory (SAI). Secondary Outcome measures will include the Chelsea Critical Care Physical Assessment Tool (CPAx) and a 5 question patient satisfaction questionnaire. Outcome measures will be taken at ICU discharge, at one week post ICU discharge and at three weeks after ICU discharge to determine physical and psychological recovery, along with evaluating overall study feasibility. It is expected that engaging patients in their rehabilitation plan will focus physiotherapy treatment and improve physical recovery. It is hypothesized that the RECAP will reassure, support and empower patients to directly affect their psychological recovery in the first three weeks after critical illness.

The User Centred Critical Care Discharge Information Pack (UCCDIP) and instructions, designed by Bench and Day (2012), will be used as a component of the RECAP. These are being used with the authors permission.
The application relates to the technical field of nano materials, in particular to an application of a copper-antimony-sulfur nano material, which is used for adsorbing to the surface of bacteria and killing the bacteria, but not adsorbing to the surface of animal cells, namely a selective sterilization application. The copper-antimony-sulfur nano material is obviously adsorbed on the surface of bacteria when acting with the bacteria; when the copper-antimony-sulfur nanomaterial acts on mammalian cells, it cannot adsorb to the surface of the cells. The copper-antimony-sulfur nanomaterial can act with-OH, -c=o and C-O of peptidoglycan of bacterial cell walls. Further theoretical calculations prove that the copper-antimony-sulfur nanomaterial has the lowest adsorption energy, i.e., the most stable conformation, with two O atoms from muramic acid. The mechanism of the copper-antimony-sulfur nano material capable of selectively adsorbing and sterilizing is a special action relationship between the copper-antimony-sulfur nano material and the bacterial cell wall, and particularly the special action relationship between the copper-antimony-sulfur nano material and cell wall acid contained in the bacterial cell wall is mainly that the mammalian cell does not have the action site. The application also provides an antibacterial composition containing the copper-antimony-sulfur nanomaterial.
For intravenous use only. The optimal dose of doxercalciferol injection must be carefully determined for each patient.

The recommended initial dose of doxercalciferol injection is 4 mcg administered intravenously as a bolus dose 3 times weekly at the end of dialysis (approximately every other day). The initial dose should be adjusted, as needed, in order to lower blood iPTH into the range of 150 to 300 pg/mL. The dose may be increased at 8-week intervals by 1 mcg to 2 mcg if iPTH is not lowered by 50% and fails to reach the target range. Dosages higher than 18 mcg weekly have not been studied. Drug administration should be suspended if iPTH falls below 100 pg/mL and restarted one week later at a dose that is at least 1 mcg lower than the last administered dose. During titration, iPTH, serum calcium, and serum phosphorus levels should be obtained weekly. If hypercalcemia, hyperphosphatemia, or a serum calcium times phosphorus product greater than 55 mg2/dL2 is noted, the dose of doxercalciferol injection should be decreased or suspended and/or the dose of phosphate binders should be appropriately adjusted. If suspended, the drug should be restarted at a dose that is 1 mcg lower. 

Dosing must be individualized and based on iPTH levels with monitoring of serum calcium and serum phosphorus levels. Table 5 presents a suggested approach in dose titration:
The experimental arm will receive a product "slim water", which contains 150 mg magnesium lactate and 2000 mg L-carnitine. The purpose is to follow the patients and examine several metabolic parameters over time (liver function test, lipid profile, liver fat content, etc.) and by that to show and prove the positive effect of the experimental treatment over placebo.
A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST) and controlled attenuation parameter (CAP) score were significantly decreased only in the soy isoflavone group (P < 0.05). A significant decline in the gamma glutamyl transferase (GGT) level was observed only in the placebo group (P = 0.017). A significant increase in the serum level of fetuin A was shown in both groups at the end of the trial with a significantly greater increment in the soy isoflavone group compared to the placebo group (P < 0.05). The changes in the serum level of FGF-21 were not significant in any of the two groups. Steatosis grade significantly improved only in the soy isoflavone group (P = 0.045). There was no significant change in the fibrosis grade in the groups. Soy isoflavone intake led to a decrease in ALT, AST, CAP score, steatosis grade and an increase in the level of fetuin A. However, no significant changes were observed in the fibrosis grade and serum levels of GGT and FGF-21.
Participant will receive 3 single-dose treatments with 2-week washout between each treatment. At each of 3 treatments, participants will receive 100mg torpiramate, 2mg lorazepam, or placebo. Treatment order is randomized. All participants in this arm will receive all 3 treatments.
One of the major hurdles of cellular therapies for the treatment of liver failure is the low availability of functional human hepatocytes. Although embryonic stem (ES) cells represent a potential cell source for therapy, current methods for differentiation result in mixed cell populations or low yields of the cells of interest. The present invention provides for a rapid, direct differentiation method that yields a homogeneous population of endoderm-like cells with 95% purity. In one embodiment, mouse ES cells cultured on top of collagen-sandwiched hepatocytes differentiate and proliferate into a uniform and homogeneous cell population of endoderm-like cells. The endoderm-like cell population was positive for Foxa2, Sox17 and AFP, and could further differentiate into hepatocyte-like cells that demonstrate hepatic morphology, functionality, and gene and protein expression. Incorporating the hepatocyte-like cells into a bioartificial liver device to treat fulminant hepatic failure improved animal survival, thereby underscoring the therapeutic potential of these cells.
PURPOSE:To arbitrarily change an analysis parameter with an operator by loading all the content of a PROM card in a SRAM having a backup function in a subject device main body by using a memory card and executing electrocardiogram measurement processing according to a program in the SRAM. CONSTITUTION:When a card detecting part 8 detects that a card inserted into an electrocardiogram analyzing device 12 is a PROM card 13, a main control part 7 of the electrocardiogram analyzing device 12 selects the chip of a memory in the PROM card 13 and loads all the content in the PROM card 13 in a memory (SRAM) 6 incorporated in the body. After the loading is completed, chip selection for the memory in the PROM card 13 is detached to the memory (SRAM) 6 of the body. After that, analysis processing is executed with one part in the memory (SRAM) 6 as a program area. Further, after the loading in the memory (SRAM) 6 is completed, the analysis parameter can be arbitrarily set by an operation part 9. Thus, detailed inspection corresponding to a patient can be executed.
1,235,409. Hydrazinoquinoline derivatives. SMITH KLINE & FRENCH LABORATORIES. 25 Sept., 1969 [26 Oct., 1968], No. 47352/69. Heading C2C. Novel hydrazinoquinoline derivatives of the general formula wherein Het is a heterocyclic aryl group, R is a hydrogen atom or a C 1-4  alkyl group and R<SP>1</SP> is a hydrogen or halogen atom or a C 1-4  alkyl, C 1-4  alkoxy or trifluoromethyl group, and pharmaceutically acceptable acid addition salts thereof are prepared by reaction of a hydrazinoquinoline of the general formula with a heterocyclic aldehyde of the general formula HetCHO, followed optionally by salification of the product. 2,6 - Dimethyl - 4 - hydrazinoquinoline is prepared by reaction of 4-chloro-2,6-dimethylquinoline with hydrazine hydrate. Pharmaceutical compositions having anticestode, antibacterial and antifungal activity comprise, as active ingredient, a hydrazinoquinoline derivative of the first general formula above or a pharmaceutically acceptable acid addition salt thereof, in association with a non- toxic diluent or excipient therefor, and may be administered orally.
Water-soluble, 2-carboxamido derivatives of a tetracycline antibiotic are produced by reacting the tetracycline antibiotic in an inert solvent with formaldehyde and an amine of formula R-NH-Z-SO2X wherein R is H, C1- 4 alkyl or C1- 4 hydroxyalkyl; Z is CH2 or CH2 = CH2; and X is OH when Z is CH2 or X is H or SH when Z is CH2-CH2.  Specified tetracycline antibiotics are tetracycline, 7 - chlorotetracycline, 5-hydroxytetracycline, 7 - chloro - 6 - demethyl tetracycline and 6-demethyl tetracycline. The tetracycline antibiotic may be used as free base or as a salt with an acid, e.g. HCl or a base, e.g. sodium. Typical amines are aminomethane sulphonic acid, methylamino methane sulphonic acid, ethylaminomethane sulphonic acid, n-butylaminomethane sulphonic acid, beta - hydroxyethylaminomethane sulphonic acid, 1 - amino - 2 - ethane sulphinic acid, and 1-amino-2-ethane thiosulphonic acid.  The amine may be used in free acid form or as a salt with an inorganic or organic base including a basic antibiotic such as kanamycin, streptomycin or erythromycin.  Pharmaceutical compositions comprise one or more of the above tetracycline derivatives and a carrier.